Patents by Inventor Matthias Busemann

Matthias Busemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-benzodiazepines
    Patent number: 9890147
    Abstract: What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: February 13, 2018
    Assignee: Bayer Pharma Aktiengesellshaft
    Inventors: Stephan Siegel, Stefan Bäurle, Arwed Cleve, Bernard Haendler, Amaury Ernesto Fernandez-Montalvan, Ursula Mönning, Sabine Krause, Pascale Lejeune, Norbert Schmees, Matthias Busemann, Simon Holton, Joachim Kuhnke
  • Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)
    Patent number: 9714266
    Abstract: The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: July 25, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Bothe, Matthias Busemann, Naomi Barak, Andrea Rotgeri, Oliver Martin Fischer, Tobias Marquardt
  • 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
    Patent number: 9512169
    Abstract: The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: December 6, 2016
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Bothe, Matthias Busemann, Oliver Martin Fischer, Naomi Barak, Andrea Rotgeri, Tobias Marquardt, Christian Stegmann
  • Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
    Patent number: 9487554
    Abstract: The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: November 8, 2016
    Assignees: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Bothe, Naomi Barak, Matthias Busemann, Oliver Martin Fischer, Andrea Rotgeri, Isabella Gashaw, Ingo Hartung, Tobias Marquardt
  • BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES
    Publication number: 20160129011
    Abstract: BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders, are described. Furthermore, the use of BET protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control is described.
    Type: Application
    Filed: February 17, 2014
    Publication date: May 12, 2016
    Inventors: Stephan SIEGEL, Stefan BÄURLE, Arwed CLEVE, Bernard HAENDLER, Amaury Ernesto FERNÁNDEZ-MONTALVÁN, Ursula MÖNNING, Sabine KRAUSE, Pascale LEJEUNE, Matthias BUSEMANN, Joachim KUHNKE
  • ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3)
    Publication number: 20160024142
    Abstract: The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis.
    Type: Application
    Filed: February 18, 2014
    Publication date: January 28, 2016
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich BOTHE, Matthias BUSEMANN, Naomi BARAK, Andrea ROTGERI, Oliver Martin FISCHER, Tobias MARQUARDT
  • 3-SUBSTITUTED ESTRA-1,3,5(10),16-TETRAENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAME, AND USE THEREOF FOR THE PRODUCTION OF MEDICAMENTS
    Publication number: 20150210734
    Abstract: The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 30, 2015
    Inventors: Ulrich Bothe, Matthias Busemann, Oliver Martin Fischer, Naomi Barak, Andrea Rotgeri, Tobias Marquardt, Christian Stegmann
  • 2,3-BENZODIAZEPINES
    Publication number: 20150203483
    Abstract: What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.
    Type: Application
    Filed: August 13, 2013
    Publication date: July 23, 2015
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Stephan Siegel, Stefan Bäurle, Arwed Cleve, Bernard Haendler, Amaury Ernesto Fernandiez-Montalvan, Ursula Mönning, Sabine Krause, Pascale Lejeune, Norbert Schmees, Matthias Busemann, Simon Holton, Joachim Kuhnke
  • Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
    Publication number: 20140249119
    Abstract: The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.
    Type: Application
    Filed: September 24, 2012
    Publication date: September 4, 2014
    Inventors: Ulrich Bothe, Naomi Barak, Matthias Busemann, Oliver Martin Fischer, Andrea Rotgeri, Isabella Gashaw, Ingo Hartung, Tobias Marquardt